|  | Training cohort (n = 152) | Validation cohort (n = 67) | p value |
---|---|---|---|---|
metastasis | no | 96 (63.2%) | 42 (62.7%) | 1 |
 | yes | 56 (36.8%) | 25 (37.3%) |  |
gender | female | 37 (24.3%) | 16 (23.9%) | 1 |
 | male | 115 (75.7%) | 51 (76.1%) |  |
age | < 55 | 89 (58.6%) | 35 (52.2%) | 0.471022503 |
 | ≥ 55 | 63 (41.4%) | 32 (47.8%) |  |
PLR | < 260 | 134 (88.2%) | 55 (82.1%) | 0.322032508 |
 | ≥ 260 | 18 (11.8%) | 12 (17.9%) |  |
NLR | < 3.8 | 107 (70.4%) | 50 (74.6%) | 0.632751819 |
 | ≥ 3.8 | 45 (29.6%) | 17 (25.4%) |  |
LMR | < 5.5 | 129 (84.9%) | 56 (83.6%) | 0.968289603 |
 | ≥ 5.5 | 23 (15.1%) | 11 (16.4%) |  |
SII | < 1185 | 113 (74.3%) | 49 (73.1%) | 0.983563436 |
 | ≥ 1185 | 39 (25.7%) | 18 (26.9%) |  |
clinical classification | 1–2 | 22 (14.5%) | 10 (14.9%) | 1 |
 | 3–4 | 130 (85.5%) | 57 (85.1%) |  |
T classification | 1–2 | 78 (51.3%) | 30 (44.8%) | 0.456065962 |
 | 3–4 | 74 (48.7%) | 37 (55.2%) |  |
N classification | 0, 1 | 89 (58.6%) | 40 (61.5%) | 0.681561 |
 | 2, 3 | 63 (41.4%) | 25 (38.5%) |  |
EBv.DNA | < 400 | 120 (78.9%) | 53 (79.1%) | 1 |
 | ≥ 400 | 32 (21.1%) | 14 (20.9%) |  |
BMI | < 28 | 131 (86.2%) | 60 (89.6%) | 0.63962412 |
 | ≥ 28 | 21 (13.8%) | 7 (10.4%) |  |
BSA | < 1.5 | 11 (7.2%) | 3 (4.5%) | 0.558705859 |
 | ≥ 1.5 | 141 (92.8%) | 64 (95.5%) |  |